The total number of records retrieved from this search are 7. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4981	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman malignant biphasic mesothelioma cell line	Cell lineMTSO-211H	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result78% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4982	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drugs pemetrexed 0.0026 mg/ml + cisplatin 0.0625	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman malignant biphasic mesothelioma cell line	Cell lineMTSO-211H	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result35% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4983	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drugs pemetrexed 0.0026 mg/ml + carboplatin 0.0625	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman malignant biphasic mesothelioma cell line	Cell lineMTSO-211H	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result22% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4990	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman malignant biphasic mesothelioma cell line	Cell lineMTSO-211H	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP per cell	In-vitro result100% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4991	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman malignant biphasic mesothelioma cell line	Cell lineMTSO-211H	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP per cell	In-vitro result80% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4992	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman malignant biphasic mesothelioma cell line	Cell lineMTSO-211H	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP per cell	In-vitro result60% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512
IDOV_4993	Virus nameAdenovirus	Virus strainONCOS-102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus having 24 bp deletion in Rb binding site of E1A region and consisting of chmeric capsid protein and Human GM-CSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human GM-CSF gene	Source of cell lineDSMZ Germany	Origin of cell lineHuman malignant biphasic mesothelioma cell line	Cell lineMTSO-211H	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP per cell	In-vitro result20% cell viability after 3 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis	Immunogenic effectNA	Clinical trialNA	PMID27287512